1380426-88-9

Basic information

• Product Name: 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone
• Synonyms: 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone
• CAS NO: 1380426-88-9
• Molecular Weight: 517.938
• Mol File: 1380426-88-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone(1380426-88-9)
• EPA Substance Registry System: 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone(1380426-88-9)

Safety Data

• Hazardous Substances Data: 1380426-88-9(Hazardous Substances Data)

Upstream product

• 1380429-33-3 (E)-1-chloro-4-(4-(2-nitrovinyl)phenoxy)-2-(trifluoromethyl)benzene 
• 1380429-22-0 methyl 2-formyl-3-(1-methyl-1H-pyrazol-4-yl)propanoate 
• 1380429-36-6 5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-(nitroamino)-4(1H)-pyrimidinone 
• 1380429-39-9 1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-(nitroamino)-4(1H)-pyrimidinone 
• 1380429-35-5 2-(4-(4-chloro-3-(trifluoromethyl)phenoxy)phenyl)ethanamine 
• 516481-95-1 4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}benzaldehyde 
• 224776-32-3 methyl 3-(1-methyl-1H-pyrazol-4-yl)propanoate 
• 1295583-21-9 methyl (2E)-3-(1-methyl-1H-pyrazol-4-yl)prop-2-enoate 
• 689251-97-6 (E)-3-(1-methyl-1H-pyrazol-4-yl)acrylic acid 
• 25016-11-9 1-methylpyrazole-4-carbaldehyde 

Relevant articles and documents

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).